Patricia LoRusso, D.O., is the Associate Director of Innovative Medicine at Yale Cancer Center. As a medical oncologist, Dr. LoRusso has been performing clinical and translational research in early-phase clinical trials for over 30 years, with the first 25 years at Karmanos Cancer Institute and, since 2014, at Yale.
Dr. LoRusso has served on the Board of Scientific Counselors at the National Cancer Institute (NCI) and has chaired its Cancer Therapy Evaluation Program (CTEP) Investigational Drug Steering Committee, the scientific committee of the American Association for Cancer Research, the education and scientific committees of the American Society of Clinical Oncology, and many peer-reviewed study sections and NCI committees.
Dr. LoRusso is a former editor of Investigational New Drugs and is currently on the editorial board for Clinical Cancer Research. She has authored over 200 peer-reviewed articles in cancer research and is internationally recognized as an expert in Phase 0 and PK/PD-driven trial design for oncology.
Dr. LoRusso earned a Michigan State University (MSU) Distinguished Alumni Award in 2014 and received, in 2015, an Honorary Doctorate of Science from MSU. In 2022, she was awarded the Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research from the American Association for Cancer Research.
Dr. LoRusso received her D.O. from Michigan State University. She completed a fellowship at Wayne State University and her residency at Riverside Osteopathic Hospital.